Duncan B. McLaren

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial

Nicholas D. James, Matthew R. Sydes, Noel W. Clarke et al. · The Lancet · 2015 · 1.9K citations · Full text

Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial

Joaquı́n Mateo, Núria Porta, Diletta Bianchini et al. · The Lancet Oncology · 2019 · 632 citations · Full text

Survival with Newly Diagnosed Metastatic Prostate Cancer in the “Docetaxel Era”: Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019)

Nicholas D. James, Melissa Spears, Noel W. Clarke et al. · European Urology · 2014 · 431 citations · Full text

Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol

Matthew R. Sydes, Melissa Spears, Malcolm D. Mason et al. · Annals of Oncology · 2018 · 240 citations · Full text

Clinical and patient‐reported outcomes of <scp>SPARE</scp> – a randomised feasibility study of selective bladder preservation versus radical cystectomy

Robert Huddart, Alison Birtle, Lauren Maynard et al. · British Journal of Urology · 2017 · 151 citations · Full text